Cadrenal Therapeutics Inc (NASDAQ: CVKD) has experienced a rise in its stock price by 16.76 compared to its previous closing price of 0.42. However, the company has seen a gain of 5.31% in its stock price over the last five trading days. PRNewsWire reported 2023-10-09 that PONTE VEDRA, Fla., Oct. 9, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham, CEO, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023.

Is It Worth Investing in Cadrenal Therapeutics Inc (NASDAQ: CVKD) Right Now?

Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for CVKD is 5.45M, and currently, short sellers hold a 0.22% ratio of that floaft. The average trading volume of CVKD on November 16, 2023 was 49.59K shares.

CVKD’s Market Performance

CVKD’s stock has seen a 5.31% increase for the week, with a -20.11% drop in the past month and a -37.14% fall in the past quarter. The volatility ratio for the week is 12.40%, and the volatility levels for the past 30 days are at 11.43% for Cadrenal Therapeutics Inc The simple moving average for the past 20 days is 4.47% for CVKD’s stock, with a -60.39% simple moving average for the past 200 days.

CVKD Trading at -20.76% from the 50-Day Moving Average

After a stumble in the market that brought CVKD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.75% of loss for the given period.

Volatility was left at 11.43%, however, over the last 30 days, the volatility rate increased by 12.40%, as shares sank -21.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.98% lower at present.

During the last 5 trading sessions, CVKD rose by +5.31%, which changed the moving average for the period of 200-days by -82.38% in comparison to the 20-day moving average, which settled at $0.4622. In addition, Cadrenal Therapeutics Inc saw -88.11% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CVKD starting from MURPHY JOHN RAYMOND, who purchase 2,669 shares at the price of $0.69 back on Oct 05. After this action, MURPHY JOHN RAYMOND now owns 614,792 shares of Cadrenal Therapeutics Inc, valued at $1,842 using the latest closing price.

MURPHY JOHN RAYMOND, the Director of Cadrenal Therapeutics Inc, purchase 17,331 shares at $0.70 during a trade that took place back on Oct 04, which means that MURPHY JOHN RAYMOND is holding 612,123 shares at $12,132 based on the most recent closing price.

Stock Fundamentals for CVKD

Equity return is now at value -323.09, with -248.00 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 0.04.


In a nutshell, Cadrenal Therapeutics Inc (CVKD) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.